Displaying 2161 - 2180 of 4394
FTC Requires NXP Semiconductors N.V. to Divest RF Power Amplifier Assets as a Condition of Acquiring Freescale Semiconductor Ltd.
FTC Staff Advises New York State Public Service Commission On Improving Proposal to Transform Electric Distribution System
Ginger Jin Named Director of FTC’s Bureau of Economics; Alison Oldale Named BE Deputy Director for Antitrust
FTC Amicus Brief Urges Appeals Court to Reverse District Court Ruling that Incorrectly Insulates Pharmaceutical Manufacturers from Antitrust Scrutiny
FTC Approves Final Order Preserving Competition in the U.S. Markets for Generic Drugs to Treat Certain Types of Ulcers, and Thyroid Conditions
Endo International plc, In the Matter of
Pharmaceutical companies Endo International plc and Par Pharmaceuticals, Inc. agreed to divest all of Endo’s rights and assets to generic glycopyrrolate tablets and generic methimazole tablets in order to settle FTC charges that Endo’s proposed $8 billion acquisition of Par would likely be anticompetitive. New Jersey-based generic drug marketer Rising Pharmaceuticals will acquire the divested assets. Under the settlement, Endo must supply Rising with the divested products for two years, while it transfers the manufacturing technology to Rising’s chosen third-party manufacturer. Endo also must provide technical assistance, training, and other transitional services to help Rising establish manufacturing capabilities. Without the divestitures required by the proposed order, the FTC alleges that the acquisition would combine the two most significant suppliers in the market for generic glycopyrrolate tablets, which are used with other drugs to treat certain types of ulcers, and two of only four active suppliers in the market for generic methimazole tablets, which are used to treat the body’s production of excess thyroid hormone.
In re Effexor XR Antitrust Litigation
FTC Approves Final Order Preserving Competition in U.S. Markets for Two Types of Orthopedic Devices
Wright Medical Group, Inc./Tornier N.V., In the Matter of
Wright Medical Group, Inc. and Tornier N.V. agreed to sell Tornier’s U.S. rights and assets related to its total ankle replacements and total silastic toe joint replacements to resolve FTC charges that the proposed $3.3 billion merger would illegally reduce competition for these devices. According to the complaint, the merger would likely substantially lessening competition in the U.S. markets for total ankle replacements and total silastic toe joint replacements. Under the settlement, Wright and Tornier will divest the rights and assets to these devices to Integra Lifesciences Corporation and provide Integra with intellectual property, manufacturing technology, and existing inventory, as well as other assets and assistance to ensure that Integra can effectively compete in the markets. The order also requires Wright and Tornier to supply Integra with total ankle replacements for up to three years and total silastic toe joint replacements for up to a year, while Integra transitions to become an independent competitor in these markets.
Impax Laboratories Inc./Medicis Pharmaceutical Corp./Sandoz Inc. (Solodyn)
FTC Approves Final Order Requiring National Association of Animal Breeders to Eliminate Rules that Restrict Competition among Its Members
FTC Challenges Proposed Merger of Two West Virginia Hospitals
1511002 Informal Interpretation
FTC Amicus Brief Urges Appeals Court to Reverse Decision in Case of Alleged Discrimination in Package Sizes
FTC Requires Mylan to Sell Rights to Seven Generic Pharmaceuticals as a Condition of Acquiring Perrigo Company
FTC Staff: South Carolina Should Consider the Competitive Impact of Legislation Affecting Advanced Practice Registered Nurses
1511001 Informal Interpretation
Woodman’s Food Market, Inc., Plaintiff-Appellee v. The Clorox Co. and The Clorox Sales Co., Defendants-Appellants
Displaying 2161 - 2180 of 4394